Biosense Webster study supports low and zero fluoroscopy workflow as safe, effective alternative to conventional catheter ablation

Biosense Webster Inc, a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTechi, revealed findings from a company-funded study of real-world data. Titled 'Real-world Data Affirms Safety and Effectiveness of Low/Zero Fluoroscopy Atrial Fibrillation Ablation,' the study was presented as a late-breaker at the 29th Annual International AF Symposium. The results support the use of workflows to reduce radiation exposure during catheter ablation for the treatment of paroxysmal atrial fibrillation (AFib) while maintaining safety, efficacy, and long-term patient outcomes comparable to traditional procedures. Biosense Webster's zero fluoroscopy workflow is the first and only such workflow available in a radiofrequency (RF) cardiac ablation device. The company received approval for this workflow from the US Food and Drug Administration last year, and it is available for cardiac ablation for several products in the company's portfolio, including the Thermocool Smarttouch SF catheter. This the most commonly used ablation catheter in the world for RF ablation and is fully integrated with the CARTO 3 System. The updated workflow indicates that direct imaging guidance, such as ultrasound, may be used as an alternative to fluoroscopy. Original source: Johnson & Johnson, website: http://www.jnj.com/, Copyright Johnson & Johnson Services Inc 2024.
research and development; CARTO 3 System; medical devices; Thermocool Smarttouch SF catheter; Biosense Webster; Johnson & Johnson [...]